In a case study which described a patient with advanced melanoma experiencing tumor response under ipilimumab, neoepitope analysis by NGS and epitope prediction led to identification of a single ipilimumab-responsive neoepitope-specific CD8 T cell that increased fivefold under therapy and remained stable for a 10-month period (135). Here, CD8A is linked to neoplasm.